옵션 체인은 다양한 행사가격과 만기일에 대한 Alaunos Therapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Alaunos Therapeutics에 대한 시장 심리를 평가합니다..

Alaunos Therapeutics (NASDAQ:TCRT) 주식, 옵션 체인

Alaunos Therapeutics

Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics Inc

Stifel analyst Steven Wieczynski maintains Six Flags Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>) with a Buy and lowers the price target from $64 to $52.

News

Price Target

Analyst Ratings

Stifel Maintains Buy on Six Flags Entertainment, Lowers Price Target to $52

General

NAOV

NanoVibronix Regains Nasdaq Compliance

<ul>
<li>Non-convertible and unsecured promissory note issued</li>
<li>Family office invests in promissory note</li>
<li>No warrants issued</li>
<li>Allows the business to continues to fund growth initiatives across the business</li>
<li>Board changes with the appointment of Richard Paolone, Eric Corbett and Angel Liriano, and the resignation of Hugh Williams and Jonathan Hart. &nbsp;</li>
</ul>
New York, NY, April 11, 2025 (GLOBE NEWSWIRE) -- Mixed Martial Arts Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMA#NYSE">MMA</a>) ("MMA" or the "Company"), a pioneering technology company seeking to aggregate and drive participation in combat sports, today announced that it entered into a non-dilutive and unsecured $2,000,000 Revolving Loan Agreement dated April 7, 2025 (the "Revolving Loan Agreement"). The Revolving Loan accrues interest at a rate of 14% per annum and matures 12 months from issuance.
As part of the financing, Hugh Williams and Jonathan Hart resigned as directors of the Company, and Richard Paolone, Eric Corbett and Angel Liriano were appointed as directors of the Company.
Nick Langton, Founder and CEO of MMA, commented on the developments, stating, "Securing this financing is a significant achievement for MMA, reinforcing our balance sheet and providing the working capital needed to support our operations. I'm thrilled to welcome Richard, Eric, and Angel to our Board. Their diverse experience and strong leadership will bring fresh perspectives and valuable guidance as we continue to advance our community offerings within the sector and unlock value for our shareholders. I would also like to express my deep appreciation to Hugh and Jonathan for their dedication and meaningful contributions to MMA's journey. With strong leadership in place and a clear strategic path forward, we believe MMA is entering a dynamic new chapter of growth and opportunity."

Financing

Mixed Martial Arts Group Limited Announces It Entered Into A Non-Dilutive And Unsecured $2M Revolving Loan Agreement Dated April 7, 2025

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

JNVR

Janover Purchases ~$5M Of Solana As Part Of Treasury Strategy

Ratings for Wolverine World Wide (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WWW#NYSE">WWW</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $20.57, a high estimate of $26.00, and a low estimate of $17.00. A decline of 16.75% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1744372886_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Wolverine World Wide. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;---------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Anna Andreeva &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $18.00&#x7C;$27.00 &#x7C; 
&#x7C;Jim Duffy &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $19.00&#x7C;$27.00 &#x7C; 
&#x7C;Jay Sole &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $26.00&#x7C;$29.00 &#x7C; 
&#x7C;Jonathan Komp &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $18.00&#x7C;$21.00 &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Lowers &#x7C;Market Perform &#x7C; $17.00&#x7C;$23.00 &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $23.00&#x7C;$23.00 &#x7C; 
&#x7C;Dana Telsey &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $23.00&#x7C;$23.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Wolverine World Wide. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Wolverine World Wide compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Wolverine World Wide's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Wolverine World Wide's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WWW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Wolverine World Wide analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Wolverine World Wide</h2>
Wolverine World Wide Inc is engaged in designing, manufacturing, sourcing, marketing, licensing, and distributing branded footwear, apparel, and accessories. The company's segment includes Active Group; Work Group; Corporate and Other. It generates maximum revenue from the Active Group segment. Active Group segment consists of Merrell footwear and apparel, Saucony footwear and apparel, Sweaty Betty activewear, and Chaco footwear.
<h3>Unraveling the Financial Story of Wolverine World Wide</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Decline in Revenue: Over the 3M period, Wolverine World Wide faced challenges, resulting in a decline of approximately -6.08% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 4.83%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Wolverine World Wide's ROE excels beyond industry benchmarks, reaching 8.03%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Wolverine World Wide's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.39%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.6, caution is advised due to increased financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 7 Analyst Ratings Have To Say About Wolverine World Wide

In the preceding three months, 8 analysts have released ratings for Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $12.25, a high estimate of $16.00, and a low estimate of $8.00. This current average represents a 1.53% decrease from the previous average price target of $12.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1744372878_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Teladoc Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Lowers &#x7C;Neutral &#x7C; $8.00&#x7C;$9.50 &#x7C; 
&#x7C;David Roman &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $13.00&#x7C;$16.00 &#x7C; 
&#x7C;Jessica Tassan &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $12.00&#x7C;$13.00 &#x7C; 
&#x7C;David Roman &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $16.00&#x7C;$14.00 &#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Raises &#x7C;Neutral &#x7C; $13.50&#x7C;$11.50 &#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Raises &#x7C;Neutral &#x7C; $11.50&#x7C;$10.50 &#x7C; 
&#x7C;Sean Dodge &#x7C;RBC Capital &#x7C;Raises &#x7C;Outperform &#x7C; $12.00&#x7C;$11.00 &#x7C; 
&#x7C;Michael Wiederhorn &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Outperform &#x7C; $12.00&#x7C;$14.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Teladoc Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Teladoc Health's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Teladoc Health's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Teladoc Health</h2>
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with Better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.
<h3>A Deep Dive into Teladoc Health's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3M period, Teladoc Health faced challenges, resulting in a decline of approximately -3.03% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teladoc Health's net margin excels beyond industry benchmarks, reaching -7.56%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Teladoc Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -3.23%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Teladoc Health's ROA excels beyond industry benchmarks, reaching -1.37%. This signifies efficient management of assets and strong financial health.
Debt Management: Teladoc Health's debt-to-equity ratio is below the industry average at 1.06, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TDOC

Forecasting The Future: 8 Analyst Projections For Teladoc Health

Analysts' ratings for Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) over the last quarter vary from bullish to bearish, as provided by 28 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">19</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">11</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Walmart, presenting an average target of $108.14, a high estimate of $120.00, and a low estimate of $91.00. Observing a 4.46% increase, the current average has risen from the previous average price target of $103.52. 
<img src="https://www.benzinga.com/files/images/story/2025/1744372868_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Walmart among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;---------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;David Belinger &#x7C;Mizuho &#x7C;Announces &#x7C;Outperform &#x7C; $105.00&#x7C;- &#x7C; 
&#x7C;Michael Lasser &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $110.00&#x7C;$112.00 &#x7C; 
&#x7C;Steven Shemesh &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $102.00&#x7C;$107.00 &#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Outperform &#x7C; $115.00&#x7C;$115.00 &#x7C; 
&#x7C;Mark Astrachan &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $91.00&#x7C;$93.00 &#x7C; 
&#x7C;Rupesh Parikh &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Outperform &#x7C; $95.00&#x7C;$110.00 &#x7C; 
&#x7C;Mark Astrachan &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $93.00&#x7C;$99.00 &#x7C; 
&#x7C;Greg Melich &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;Outperform &#x7C; $100.00&#x7C;$107.00 &#x7C; 
&#x7C;Robert Drbul &#x7C;Guggenheim &#x7C;Maintains &#x7C;Buy &#x7C; $100.00&#x7C;$100.00 &#x7C; 
&#x7C;Steven Shemesh &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $107.00&#x7C;$109.00 &#x7C; 
&#x7C;Michael Lasser &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $112.00&#x7C;$113.00 &#x7C; 
&#x7C;Bill Kirk &#x7C;Roth MKM &#x7C;Raises &#x7C;Buy &#x7C; $108.00&#x7C;$97.00 &#x7C; 
&#x7C;John Vinh &#x7C;Keybanc &#x7C;Raises &#x7C;Overweight &#x7C; $105.00&#x7C;$100.00 &#x7C; 
&#x7C;Peter Keith &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $114.00&#x7C;$118.00 &#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Outperform &#x7C; $115.00&#x7C;$115.00 &#x7C; 
&#x7C;Peter Keith &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $118.00&#x7C;$93.00 &#x7C; 
&#x7C;Peter Benedict &#x7C;Baird &#x7C;Raises &#x7C;Outperform &#x7C; $115.00&#x7C;$100.00 &#x7C; 
&#x7C;Seth Sigman &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $108.00&#x7C;$98.00 &#x7C; 
&#x7C;Simeon Gutman &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $115.00&#x7C;$106.00 &#x7C; 
&#x7C;Joseph Feldman &#x7C;Telsey Advisory Group&#x7C;Raises &#x7C;Outperform &#x7C; $115.00&#x7C;$105.00 &#x7C; 
&#x7C;Scot Ciccarelli &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $111.00&#x7C;$98.00 &#x7C; 
&#x7C;Paul Lejuez &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $120.00&#x7C;$98.00 &#x7C; 
&#x7C;Christopher Horvers &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $112.00&#x7C;$97.00 &#x7C; 
&#x7C;Rupesh Parikh &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $110.00&#x7C;$100.00 &#x7C; 
&#x7C;Edward Kelly &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $108.00&#x7C;$100.00 &#x7C; 
&#x7C;Michael Lasser &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $113.00&#x7C;$100.00 &#x7C; 
&#x7C;Simeon Gutman &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $106.00&#x7C;$100.00 &#x7C; 
&#x7C;Steven Shemesh &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $105.00&#x7C;$105.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Walmart. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Walmart compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Walmart's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Walmart's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WMT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Walmart analyst ratings.</a>
<h2>All You Need to Know About Walmart</h2>
Walmart serves as a leading retailer in the United States, with its strategy predicated on superior operating efficiency and offering the lowest priced goods to consumers to drive robust store traffic and product turnover. Walmart augmented its low-price business strategy by offering a convenient one-stop shopping destination with the opening of its first supercenter in 1988.Today, Walmart operates over 4,600 stores in the United States (5,200 including Sam's Club) and over 10,000 locations globally. Walmart generated over $460 billion in domestic namesake sales in fiscal 2025, with Sam's Club contributing another $90 billion to the company's top line. Internationally, Walmart generated $120 billion in sales. The retailer serves around 270 million customers globally each week.
<h3>Walmart's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Walmart's revenue growth over a period of 3M has been noteworthy. As of 31 January, 2025, the company achieved a revenue growth rate of approximately 4.13%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Staples sector.
Net Margin: Walmart's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.91% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Walmart's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.87%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.0%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.66.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

28 Analysts Assess Walmart: What You Need To Know

ORLY Finishes Higher on the Day as Broad Market Finishes Lower
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/10205155/Screenshot-2025-04-10-at-4.44.18%E2%80%AFPM-1006x1024.png" alt="" class="wp-image-10314" /></figure>
O&#8217;Reilly Automotive, Inc. (ORLY) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 11:26 AM on April 10th, a significant trading signal occurred for O&#8217;Reilly Automotive (ORLY) as it demonstrated a Power Inflow at a price of $1354.28. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in O&#8217;Reilly&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in O&#8217;Reilly&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for ORLY, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; &nbsp; <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>&nbsp; which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $1354.28. The returns on the High price ($1392.96) and Close price ($1373.36) after the Power Inflow are respectively 2.9% and 1.4%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Performance results are are not Indicative of future results

Equities

WIIM

Technicals

Signals

Trading Ideas

O'Reilly Automotive Up 2.9% After Key Signal, Even As Market Ends in Red

Stifel analyst Matthew Smith maintains Treehouse Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THS#NYSE">THS</a>) with a Hold and lowers the price target from $35 to $26.

Stifel Maintains Hold on Treehouse Foods, Lowers Price Target to $26

Ratings for Joby Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $8.33, with a high estimate of $10.00 and a low estimate of $5.00. Observing a downward trend, the current average is 3.92% lower than the prior average price target of $8.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1744372858_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Joby Aviation is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Kristine Liwag &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $7.00&#x7C;$10.00 &#x7C; 
&#x7C;Andres Sheppard &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Overweight &#x7C; $9.00&#x7C;$9.00 &#x7C; 
&#x7C;Chris Pierce &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $10.00&#x7C;$10.00 &#x7C; 
&#x7C;Bill Peterson &#x7C;JP Morgan &#x7C;Lowers &#x7C;Underweight &#x7C; $5.00&#x7C;$6.00 &#x7C; 
&#x7C;Amit Dayal &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $9.00&#x7C;$9.00 &#x7C; 
&#x7C;Chris Pierce &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $10.00&#x7C;$8.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Joby Aviation. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Joby Aviation compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Joby Aviation's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Joby Aviation's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/JOBY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Joby Aviation analyst ratings.</a>
<h2>Delving into Joby Aviation's Background</h2>
Joby Aviation Inc is a transportation company developing an all-electric, vertical take-off and landing (eVTOL) air taxi for commercial passenger service. Its Joby eVTOL aircraft is designed to transport a pilot and up to four passengers or an expected payload of up to 1,000 pounds at speeds of up to 200 mph. The aircraft is optimized for urban routes, with a target range of up to 100 miles on a single charge. The company is also developing an app-based platform to build and operate an aerial ridesharing service powered by a network of eVTOL aircraft that it will manufacture and operate. It has one operating and reportable segment, namely flight services. Currently, the company generates all of its revenue from flight services provided to the Department of Defense in the United States.
<h3>Joby Aviation: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Joby Aviation's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -94.67%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -447776.36%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -29.09%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -22.72%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Joby Aviation's debt-to-equity ratio is below the industry average at 0.03, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

JOBY

Beyond The Numbers: 6 Analysts Discuss Joby Aviation Stock

In the last three months, 8 analysts have published ratings on HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $112.5, a high estimate of $125.00, and a low estimate of $94.00. Marking an increase of 0.22%, the current average surpasses the previous average price target of $112.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1744372848_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive HealthEquity. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Alexander Paris &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $112.00&#x7C;$112.00 &#x7C; 
&#x7C;David Roman &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $94.00&#x7C;$107.00 &#x7C; 
&#x7C;C. Gregory Peters &#x7C;Raymond James &#x7C;Lowers &#x7C;Strong Buy &#x7C; $115.00&#x7C;$120.00 &#x7C; 
&#x7C;Scott Schoenhaus &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $110.00&#x7C;$120.00 &#x7C; 
&#x7C;Alexander Paris &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $112.00&#x7C;$112.00 &#x7C; 
&#x7C;Alexander Paris &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $112.00&#x7C;$112.00 &#x7C; 
&#x7C;Stan Berenshteyn &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $125.00&#x7C;$110.00 &#x7C; 
&#x7C;C. Gregory Peters &#x7C;Raymond James &#x7C;Raises &#x7C;Outperform &#x7C; $120.00&#x7C;$105.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to HealthEquity. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of HealthEquity compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of HealthEquity's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into HealthEquity's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HQY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on HealthEquity analyst ratings.</a>
<h2>Unveiling the Story Behind HealthEquity</h2>
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
<h3>HealthEquity: Financial Performance Dissected</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: HealthEquity's remarkable performance in 3M is evident. As of 31 January, 2025, the company achieved an impressive revenue growth rate of 18.84%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: HealthEquity's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.46% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): HealthEquity's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.24%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): HealthEquity's ROA stands out, surpassing industry averages. With an impressive ROA of 0.76%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.52.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: HealthEquity Through The Eyes Of 8 Analysts

Across the recent three months, 8 analysts have shared their insights on Revolve Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Revolve Gr and provided 12-month price targets. The average target is $29.75, accompanied by a high estimate of $40.00 and a low estimate of $19.00. This current average represents a 6.53% decrease from the previous average price target of $31.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1744372833_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Revolve Gr is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Anna Andreeva &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $22.00&#x7C;$35.00 &#x7C; 
&#x7C;Jim Duffy &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $28.00&#x7C;$40.00 &#x7C; 
&#x7C;Randal Konik &#x7C;Jefferies &#x7C;Announces &#x7C;Buy &#x7C; $30.00&#x7C;- &#x7C; 
&#x7C;Matt Koranda &#x7C;Roth MKM &#x7C;Raises &#x7C;Buy &#x7C; $36.00&#x7C;$35.00 &#x7C; 
&#x7C;Simeon Siegel &#x7C;BMO Capital &#x7C;Raises &#x7C;Market Perform &#x7C; $19.00&#x7C;$15.00 &#x7C; 
&#x7C;Jim Duffy &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $40.00&#x7C;$41.00 &#x7C; 
&#x7C;Trevor Young &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $26.00&#x7C;$25.00 &#x7C; 
&#x7C;Ashley Owens &#x7C;Keybanc &#x7C;Announces &#x7C;Overweight &#x7C; $37.00&#x7C;- &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Revolve Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Revolve Gr compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Revolve Gr's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Revolve Gr's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RVLV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Revolve Gr analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Revolve Gr's Background</h2>
The Revolve Group is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the US, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of unique products from emerging fashion brands with less than $10 million in annual sales.
<h3>A Deep Dive into Revolve Gr's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Revolve Gr's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 13.95%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Revolve Gr's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 4.2%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Revolve Gr's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.87%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Revolve Gr's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.85% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Revolve Gr's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RVLV

Beyond The Numbers: 8 Analysts Discuss Revolve Gr Stock

Stifel analyst Brad Reback maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Buy and lowers the price target from $340 to $275.

Stifel Maintains Buy on MongoDB, Lowers Price Target to $275

Truist Securities analyst William Stein initiates coverage on MACOM Technology Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>) with a Buy rating and announces Price Target of $125.

Initiation

MTSI

Truist Securities Initiates Coverage On MACOM Technology Solns with Buy Rating, Announces Price Target of $125

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>B of A Securities analyst Kenneth Bruce upgraded the rating for American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) from Neutral to Buy and lowered the price target from $325 to $274. American Express shares closed at $246.89 on Thursday. <a href="https://www.benzinga.com/quote/axp/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Noah Poponak upgraded Huntington Ingalls Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>) from Sell to Buy and raised the price target from $145 to $234. Huntington Ingalls shares closed at $200.89 on Thursday. <a href="https://www.benzinga.com/quote/hii/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Noah Poponak upgraded the rating for Northrop Grumman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) from Sell to Neutral and raised the price target from $424 to $521. Northrop Grumman shares closed at $516.09 on Thursday. <a href="https://www.benzinga.com/quote/noc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst Angie Storozynski upgraded California Water Service Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWT#NYSE">CWT</a>) from Neutral to Buy and announced a $54 price target. California Water shares closed at $48.50 on Thursday. <a href="https://www.benzinga.com/quote/cwt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Gavin Parsons upgraded the rating for Booz Allen Hamilton Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) from Buy to Neutral and cut the price target from $150 to $109. Booz Allen Hamilton shares closed at $108.81 on Thursday.  <a href="https://www.benzinga.com/quote/BAH/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NOC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="592" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11075525/image-80-1024x592.png" alt="" class="wp-image-867770" style="width:533px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11075525/image-80-1024x592.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11075525/image-80-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11075525/image-80-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/11075525/image-80.png 1098w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44734419/top-2-real-estate-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Real Estate Stocks That May Keep You Up At Night This Month</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

This Northrop Grumman Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday

Morgan Stanley analyst Kristine Liwag maintains FTAI Aviation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) with a Overweight and lowers the price target from $168 to $138.

FTAI

Morgan Stanley Maintains Overweight on FTAI Aviation, Lowers Price Target to $138

Innventure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INV#NASDAQ">INV</a>) reported quarterly losses of $(1.42) per share. The company reported quarterly sales of $456.00 thousand which beat the analyst consensus estimate of $455.00 thousand by 0.22 percent. This is a 1.33 percent increase over sales of $450.00 thousand the same period last year.

Earnings

Earnings Beats

Innventure Q4 2024 GAAP EPS $(1.42), Sales $456.00K Beat $455.00K Estimate

Morgan Stanley analyst Kristine Liwag maintains Textron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) with a Equal-Weight and lowers the price target from $82 to $71.

Morgan Stanley Maintains Equal-Weight on Textron, Lowers Price Target to $71

Morgan Stanley analyst Kristine Liwag maintains Hexcel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HXL#NYSE">HXL</a>) with a Underperform and lowers the price target from $61 to $50.

Morgan Stanley Maintains Underperform on Hexcel, Lowers Price Target to $50

Tesla Inc. CEO Elon Musk, overseeing the Department of Government Efficiency (DOGE), has reportedly reduced his projected budget savings for the upcoming fiscal year.
What Happened: Musk, who initially pledged to cut $2 trillion from the federal budget during Donald Trump&#8216;s 2024 presidential campaign, has now lowered the projected savings to $150 billion. This announcement was made during a cabinet meeting on Thursday, according to the <a href="https://www.nytimes.com/2025/04/10/us/politics/musk-doge-drops-goal.html">New York Times.</a>
The Department of Government Efficiency, under Musk&#8217;s leadership, has been responsible for slashing budgets and laying off thousands of employees in Washington. However, the department&#8217;s website shows that it is far from reaching Musk&#8217;s revised&nbsp;goal of $1 trillion in&nbsp;savings for the next fiscal year.
"I'm excited to announce that we anticipate savings in '26 from reduction of waste and fraud by $150 billion," stated Musk at the cabinet meeting, referring to the fiscal year spanning October 2025 through September 2026.
Musk also called the government a "target-rich environment" for uncovering waste or fraud.
It is still uncertain whether the $150 billion represents the total projected savings or just the amount identified to date. Despite the confusion, a White House official confirmed that the $1 trillion savings target remains &#8220;the goal&#8221;, stated NY Times. 
In a Fox News interview last month, Elon Musk stated that the DOGE office was on track to cut nearly $1 trillion in government spending by the end of his tenure.
SEE ALSO:&nbsp;<a href="https://benzinga.com/25/04/44754349/bitcoins-final-crash-peter-schiff-predicts-2025-crisis-will-end-what-2008-created" target="_blank" rel="noreferrer noopener">Bitcoin&#8217;s Final Crash? Peter Schiff Predicts 2025 Crisis Will End What 2008 Created</a>
Why It Matters: Notably, Musk&#8217;s cost-cutting efforts have been criticized for errors on the department&#8217;s website, including double-counting&nbsp;the same cancellations and claiming&nbsp;credit for ending programs that concluded under previous administrations.
Bank of America (BofA) Securities recently pointed out that DOGE's savings from canceled or renegotiated contracts are apparently "overstated,&#8221; as per a Fortune report. The DOGE team reports savings of approximately $24.8 billion through contract cancellations and renegotiations as of March 30, an increase from $21.6 billion the week before that. However, experts told the publication that DOGE seemed to misinterpret the nature of government contracts, resulting in overstated figures. These contracts often include &#8216;ceiling values&#8217;—maximum limits that are typically much higher than the actual amounts spent.
The drastic drop in projected savings comes in the wake of concerns raised by financial experts about the economic impact of the job cuts initiated by the Department of Government Efficiency. Danny Moses, founder of Moses Ventures, <a href="https://www.benzinga.com/25/03/44447947/big-short-investor-danny-moses-warns-of-economic-risks-from-elon-musks-doge-induced-federal-job-cuts">had warned </a>about the economic risks from these job cuts.
Moreover, billionaire entrepreneur Mark Cuban had also cautioned about a potential economic crisis <a href="https://www.benzinga.com/markets/25/04/44666499/mark-cuban-warns-of-a-crisis-far-worse-than-2008-if-trumps-tariff-turmoil-and-elon-musks-doge-moves-continue">worse than 2008 </a>if the downsizing by the Department of Government Efficiency continues, coupled with the newly imposed tariffs. 
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/04/44735140/most-people-dont-have-the-balls-to-do-it-says-mark-cuban-praising-musk-for-going-all-in-with-his-own-money-f" target="_blank" rel="noreferrer noopener">&#8216;Most People Don&#8217;t Have The Balls To Do It,&#8217; Says Mark Cuban, Praising Musk For Going &#8216;All In&#8217; With His Own Money For His Startups</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Comments

Alaunos Therapeutics

Alaunos Therapeutics (TCRT) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌